179
Participants
Start Date
October 31, 2004
Primary Completion Date
October 31, 2007
Study Completion Date
October 31, 2007
zoledronic acid
4 mg zoledronic acid in 250 mL of calcium-free solution (i.e., 0.9% sodium chloride or 5% glucose) administered intravenously.
New York Presbyterian Hospital, New York
Hematology Oncology of Western Suffolk, Bay Shore
Syracuse Hematology/Oncology PC, Syracuse
University of Pennsylvania, Philadelphia, Philadelphia
Pennsylvania Oncology Associates, Philadelphia
Berks Oncology and Hematology Associates, West Reading
Oncology Hematology Associates, PA, Clinton
Center for Cancer and Blood Disorders, Bethesda
Maryland Oncology-Hematology PA, Columbia
Oncology Hematology Associates of Southwest VA, Salem
Charleston Hematology Oncology, Charleston
Georgia Cancer Specialists, Tucker
Augusta Oncology Associates, Augusta
MetCare Oncology, Ormond Beach
Hematology Oncology Associates PA, Pensacola
Hem/Onc Associates of Central Brevard, Rockledge
South Florida Oncology Hematology, Hollywood
Miami Cancer Care, Miami
Florida Cancer Specialists, Fort Meyers
Pasco Hernado Oncology, New Port Richey
Osceola Cancer Center, Kissimmee
Hematology Oncology Specialists, Huntsville
Baptist Regional Cancer Center, Knoxville
Dayton Oncology & Hematology, PA, Kettering
Cancer Care Center, New Albany
Providence Cancer Center, Clinical Trials Dept, Southfield
Hematology Oncology Associates of Ohio & Michigan, Lambertville
Fox Valley Hematology Oncology SC, Appleton
The Center for Cancer Care and Research, St Louis
Kansas City Cancer Center, Kansas City
St. Joseph Oncology, Inc., Saint Joseph
Hutchinson Clinic, PA, Hutchinson
Nebraska Methodist Hospital, Omaha
Hematology and Oncology Specialists, New Orleans
Myeloma Institute For Research Therapy, Little Rock
University of Arkansas, Little Rock
Center for Oncology Research & Treatment, PA, Dallas
Joe Arrington Cancer Research and Treatment Center, Lubbock
Greeley Medical Center, Greeley
Utah Hematology Oncology, Ogden
Palo Verde Hematology Oncology, Glendale
US Oncology, Tucson
New Mexico Cancer Care Associates, Santa Fe
Comprehensive Cancer Centers of Nevada, Las Vegas
Nevada Cancer Center, Las Vegas
Oncotherapeutics, West Hollywood
Pacific Shores Medical Group, Long Beach
North Valley H/O, Mission Hills
Dr. Robert P. Brouillard Inc., La Jolla
Desert Hematology Oncology Medical Group, Rancho Mirage
Pacific Cancer Medical Center, Anaheim
Hematology/Oncology Group of Orange County, Orange
Comprehensive Blood and Cancer Center, Bakersfield
Antelope Valley Cancer Center, Lancaster
California Oncology of the Central Valley, Fresno
Camino Medical Group, Sunnyvale
Bay Area Cancer Research Group, Concord
Southbay Oncology Hematology Partners, Campbell
Swedish Cancer Institute, Seattle
Western Washington Oncology, Lacey
Maine Center for Cancer Medicine - Blood Disorders, Scarborough
Center for Cancer & Hematology Disease, Cherry Hill
Central Jersey Oncology Center, East Brunswick
Hackensack University Medical Center, Hackensack
CINJ at Cooper University Hospital, Voorhees Township
Hematology & Oncology Associates of RI, Cranston
Roger Williams Hospital Medical Center, Providence
UT Southwestern Medical Center, Dallas
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY